<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795582</url>
  </required_header>
  <id_info>
    <org_study_id>22-AOI-07</org_study_id>
    <nct_id>NCT05795582</nct_id>
  </id_info>
  <brief_title>Upstroke Time Measured by Photoplethysmography</brief_title>
  <acronym>TEMPO-DIAB</acronym>
  <official_title>Upstroke Time Measured by Photoplethysmography : Comparison With the Systolic Toe Pressure Index in a Population of Diabetic Arteriopaths</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripherial arterial disease (PAD) and diabetes are major public health issues. In 2020,&#xD;
      according to the latest epidemiological data, it is estimated that there will be more than&#xD;
      one million patients with PAD and more than 3.5 million diabetic patients in France.&#xD;
&#xD;
      In the diabetic patient, screening for PAD is carried out by calculating the Toe-Brachial&#xD;
      pressure index (TBi), a technique that remains time-consuming and technically demanding,&#xD;
      which limits its use for clinical routine screening.&#xD;
&#xD;
      A new photoplethysmographic method (PPG) makes possible to determine the quality of&#xD;
      peripheral perfusion thanks to the automatic computation of the upstroke time (TMS in ms).&#xD;
&#xD;
      This method appears to be a promising, inexpensive, faster and easier technical alternative&#xD;
      to improve the dissemination of the vascular screening in diabetics.&#xD;
&#xD;
      To date, no prospective study has established a relationship between the measurement of&#xD;
      upstroke time using the PPG method and TBi in a specific diabetic population.We will perform&#xD;
      a two-centre prospective study (Nice University Hospital and Antibes Hospital) comparing the&#xD;
      two techniques. The main objective of our study will compare the values of the upstroke time&#xD;
      obtained by a PPG method and the TBi in a population of diabetic patients.&#xD;
&#xD;
      The secondary objectives will be to compare the TBi values to the ratio of the TMS&#xD;
      measurements at the toe to the reference TMS measured at the hand and to determine the&#xD;
      sensitivity-specificity of the TMS measured by PPG compared to the TBi in the detection of a&#xD;
      significant PAD in diabetics.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2023</start_date>
  <completion_date type="Anticipated">November 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of the values of upstroke time (TMS) obtained by a new method of measurement by PPG (photoplethysmographic) technique and IPSo</measure>
    <time_frame>1 hour</time_frame>
    <description>TMS measurement</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>diabetic patients with peripherial arterial disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be included during a vascular medicine consultation for follow-up or screening for vascular pathology. Each subject will have their upstroke time measured by a new method of measurement using the device POPMETRE® (Axelife, France).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>POPMETRE® (Axelife , France)</intervention_name>
    <description>Measurement with 2 devices</description>
    <arm_group_label>diabetic patients with peripherial arterial disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient &gt; 18 years, with no upper age limit&#xD;
&#xD;
          -  Vascular assessment for PAD (screening or follow-up).&#xD;
&#xD;
          -  Patient diagnosed with type 2 diabetes according to WHO diagnostic criteria (blood&#xD;
             glucose &gt; 1.26 g/l (7.0 mmol/l) after an 8-hour fast and checked twice ; or the&#xD;
             presence of symptoms of diabetes (polyuria, polydipsia, weight loss) associated with a&#xD;
             blood glucose level (on venous plasma) &gt; 2 g/l (11.1 mmol/l); or a blood glucose level&#xD;
             (on venous plasma) &gt; 2 g/l (11.1 mmol/l) 2 hours after an oral glucose load of 75 g),&#xD;
             under medical treatment or under dietary treatment alone.&#xD;
&#xD;
          -  Patient having signed the informed consent form for the study.&#xD;
&#xD;
          -  Patient with social security coverage.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under 18 years of age&#xD;
&#xD;
          -  Major amputations including transfemoral and transtibial amputations&#xD;
&#xD;
          -  Ankle or toe lesions&#xD;
&#xD;
          -  Any clinical condition of the patient not allowing measurements (acute ischaemia,&#xD;
             pain, tremors...).&#xD;
&#xD;
          -  Pregnant women, pregnant and breast feeding women, persons deprived of their freedom&#xD;
             by a judicial or administrative decision, persons hospitalised without consent who are&#xD;
             not covered by the provisions of Article L. 1121-8, and persons admitted to a health&#xD;
             or social establishment for purposes other than research.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samantha AMRANI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samantha AMRANI, Dr</last_name>
    <phone>04 92 03 38 35</phone>
    <email>amrani.s@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie BONNET</last_name>
    <phone>04 92 03 85 48</phone>
    <email>bonnet.s2@chu-nice.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CH d'Antibes</name>
      <address>
        <city>Antibes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Fabien Lareyre</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Samantha AMRANI</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>May 3, 2023</last_update_submitted>
  <last_update_submitted_qc>May 3, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

